<SEC-DOCUMENT>0001157523-22-000281.txt : 20220303
<SEC-HEADER>0001157523-22-000281.hdr.sgml : 20220303
<ACCEPTANCE-DATETIME>20220303060012
ACCESSION NUMBER:		0001157523-22-000281
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20220302
FILED AS OF DATE:		20220303
DATE AS OF CHANGE:		20220303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		22706634

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52588389.htm
<DESCRIPTION>INNATE PHARMA S.A. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-weight: bold;">&#160;Washington, D.C. 20549</div>
    <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.9pt; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Date of report: For the month of March 2022</div>
    <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Commission File Number: 001-39084</div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Innate Pharma S.A.</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt;">(Translation of registrant's name into English)</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-weight: bold;">Innate Pharma S.A.</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-weight: bold;">117 Avenue de Luminy&#8212;BP 30191</div>
    <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt; font-weight: bold;">13009 Marseille, France</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 2.3pt; font-weight: bold;">+ 33 (0) 4 30 30 30</div>
    <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt;">(Address of principal executive office)</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="margin-right: 56.8pt; margin-left: 5.55pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div style="margin-right: 56.8pt; margin-left: 5.55pt;"> <br>
    </div>
    <div style="margin-right: 56.8pt; margin-left: 5.55pt;">Form 20-F [ X ]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 40-F [ ]</div>
    <div>&#160;</div>
    <div style="margin-right: 34.45pt; margin-left: 5.55pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [&#160; ]</div>
    <div>&#160;</div>
    <div style="margin-right: 34.45pt; margin-left: 5.55pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [&#160; ]</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-weight: bold;">EXHIBIT INDEX</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z1618a104987049e6bfec6c72d2068a1d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 10%;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit</u></font></td>
            <td style="width: 90%;">
              <div style="text-align: left;"><font style="font-weight: bold; font-family: 'Times New Roman',Times,serif;"><u>Description</u></font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%;">
              <div>&#160;</div>
            </td>
            <td style="width: 90%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%;"><a href="a52588389ex99_1.htm">99.1</a></td>
            <td style="width: 90%;"><a href="a52588389ex99_1.htm">[Press Release dated March 3, 2022]</a></td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    &#160;<br>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="margin-right: 14.85pt; margin-left: 5.55pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z92610691a32441b08a0c7c6f1fdb3cf9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1" style="font-weight: bold;">INNATE PHARMA S.A.</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 7%;">
              <div>&#160;</div>
            </td>
            <td style="width: 43%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;">Date: March 3, 2022</td>
            <td style="width: 7%; padding-bottom: 2px;">By:</td>
            <td style="width: 43%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ MONDHER MAHJOUBI</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 7%;">Name:</td>
            <td style="width: 43%;">Mondher Mahjoubi</td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 7%;">Title:</td>
            <td style="width: 43%;">
              <div>Chairman of the Executive Board and Chief Executive Officer</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="font-weight: normal;"><br>
    </div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52588389ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <table cellspacing="0" cellpadding="0" border="0" id="zc0ec066040a844469f11ef420a2a06d3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 100%; text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Number of Shares and Voting Rights of Innate Pharma as of March 1, 2022</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>MARSEILLE, France--(BUSINESS WIRE)--March 3, 2022--Regulatory News: </p>
          <p> Pursuant to the article L. 233-8 II of the French &#8220;Code de Commerce&#8221; and the article 223-16 of the French stock-market authorities (<i>Autorit&#233; des March&#233;s Financiers</i>, or &#8220;<b>AMF</b>&#8221;) General Regulation, Innate Pharma SA (Euronext Paris:
            IPH; Nasdaq: IPHA) (&#8220;<b>Innate</b>&#8221; or the &#8220;<b>Company</b>&#8221;) releases its total number of shares outstanding as well as its voting rights as at March 1, 2022: </p>
          <table cellspacing="0" id="za1af4c7e74c1497c9d2f57d14871456c" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Total number of shares outstanding: </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> 79,728,657 ordinary shares </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> 6,514 Preferred Shares 2016 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;"><br>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> 7,581 Preferred Shares 2017 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Total number of theoretical voting rights (1): </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> 80,486,497 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Total number of exercisable voting rights (2): </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="padding-left: 0px;padding-right: 0px;vertical-align: bottom;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> 80,467,922 </p>
                </td>
              </tr>

          </table>
          <table cellspacing="0" id="z0cf04cca25334fd5af68eab87e47fc0b" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0px;"><i>(1) The total number of theoretical voting rights (or &#8220;gross&#8221; voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In
                    accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of
                    theoretical voting rights includes voting rights attached to AGAP 2016 (2016 Preferred Shares), i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2.</i></td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0px;"><br>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: bottom;padding-left: 0px;"><i>(2) The total number of exercisable voting rights (or &#8220;net&#8221; voting rights) is calculated without taking into account the shares held in treasury by the
                    Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.</i></td>
              </tr>

          </table>
          <p> <b>About Innate Pharma:</b> </p>
          <p> Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. </p>
          <p> Innate Pharma&#8217;s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. </p>
          <p> Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified
            proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. </p>
          <p> Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. </p>
          <p> Learn more about Innate Pharma at www.innate-pharma.com </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Information about Innate Pharma shares:</b> </p>
          <table cellspacing="0" id="z9aa34f5c40a8440298feffc2a253aa93" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> <b>ISIN code </b> </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> FR0010331421 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> <b>Ticker code </b> </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> Euronext: IPH Nasdaq: IPHA </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> <b>LEI</b> </p>
                </td>
                <td colspan="1" rowspan="1"><br>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;text-align: left;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> 9695002Y8420ZB8HJE29 </p>
                </td>
              </tr>

          </table>
          <p> <b>Disclaimer on forward-looking information and risk factors:</b> </p>
          <p> This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and
            similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which
            could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results
            from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts, the Company&#8217;s continued ability to raise capital to fund
            its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company&#8217;s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which
            could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal
            Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or on Innate Pharma&#8217;s website, and public filings and reports filed with the U.S. Securities and
            Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. </p>
          <p> This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>For additional information, please contact: <br>
            </b><br>
            <b><u>Investors and Media <br>
                </u></b><br>
            <b>Innate Pharma </b><br>
            Henry Wheeler <br>
            Tel.: +33 761 88 38 74 <br>
            Henry.wheeler@innate-pharma.fr<br>
            <br>
            <b>ATCG Press </b><br>
            Marie Puvieux (France) <br>
            Tel.: +33 (0)9 81 87 46 72 <br>
            innate-pharma@atcg-partners.com </p>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
